New research indicates that patients who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds far faster than those who stop traditional diet and exercise regimens.
Research printed in a major medical journal points out that while obese individuals can lose about a fifth of their total mass while on the medication, the mass comes back at an estimated rate of 0.8 kg per month after stopping.
"Individuals using such medications must be informed of the danger of quick rebound weight gain when the treatment ends," stated researcher Dr. Susan Jebb.
This pace of recovery means a return to original weight in about 18 months.
Analyzing Approaches
The analysis, which looked at dozens of studies involving over 9,000 of patients, contrasted the results of the injectable medications with other pills.
The team note that individuals who lose weight through dieting generally have a less rapid creep back—approximately 100 grams monthly—after stopping.
The Reason for the Quick Regain
Nutrition scientists suggest the mode of action of the jabs is key to understanding the amplified weight return.
These medications mimic a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 concentrations several times higher than normal could lead to the system to produce less of its own natural GLP-1, and may also lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition expert.
"Discontinuation of this medication leads to hunger is unsuppressed, making excessive eating far more likely."
A Chronic Issue?
Health authorities recommend the injections for people with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
Many experts contend that, considering the likelihood of relapse, the therapy should be considered long-term.
This opinion is supported by pharmaceutical companies, who state that the results "highlight the long-term nature of excess weight," comparing it to managing conditions like hypertension.
Patient Testimonies
Individuals who have discontinued the medication report a intense resurgence of cravings.
"I experienced something that goes on and I was suddenly ravenous," said one woman.
This challenge is exacerbated if patients have not developed sustainable dietary or behavioural changes during treatment.
Growing Use
Figures indicate that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.
- Use is more common among females compared to males.
- The 40s and 50s age group shows the greatest level of interest.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, clinicians emphasize that while the jabs are effective tools for weight loss, they are not a permanent solution and lasting health benefits relies on combined lifestyle changes.
